AAA confident of convincing NICE of Lutathera value

11 August 2017

Jeevan Virk, commercial director for the UK and Ireland at French molecular nuclear medicine specialist Advanced Accelerator Applications’ (Nasdaq: AAAP), admitted that it was not a shock when the National Institute for Health and Care Excellence (NICE) published draft guidance not recommending Lutathera (Lutetium Lu 177 dotatate) for treating neuroendocrine tumors of gastrointestinal and pancreatic origin.

The NICE found that the cost-effectiveness estimates for Lutathera were higher than the £20,000 ($26,440)- £30,000 ($39,660) per quality adjusted life year (QALY) normally considered as a fair price by the UK medicines cost-effectiveness watchdog, with the treatment not meeting the required end of life criteria.

“We're not really massively surprised,” Mr Virk says. “Many drugs go through a negative draft guidance stage and they go on to have a positive recommendation in the final guidance – I guess it's part of the process of going through the NICE appraisal.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK